We use own and third party cookies to improve our services and show you contents related to your browsing habits. If you go on navigating, we will consider you accept its use. Click HERE to change the settings or get more information.

Abrir el Menú Móvil

Biretix, effectively targeting acne-prone skin | Cantabria Labs

CLINICAL EFFICACY: visible results and excellent tolerability

The efficacy of Biretix products and technologies has been demonstrated in numerous clinical studies conducted by dermatologists around the world, with results published in leading international scientific and medical journals.

Consult the main Biretix clinical studies

Reduction of comedones and inflammatory lesions as evaluated by confocal microscopy

Results after 45 days treatment with Biretix:

  • Reduction in total lesion count (70.8 %)
  • Reduction in number of comedones and inflammatory lesions (65.4%)

Evaluation of Biretix in post-isotretinoin maintenance and prevention of relapse


  • Overall relapse was significantly less (17%) - Graph 1
  • High tolerance in maintenance therapy - Graph 2

Reduction in comedones and sebum normalisation


  • Confocal microscopy showed a reduction in hyperkeratinisation and inflammatory cells
  • After 8 weeks, it demonstrateda significant improvement with respect to initial conditions

Reduction in comedones and high tolerance


Synergic action of active ingredients:

  • Reduces acne lesions (-38% microcomedones, -65% macrocomedones)
  • Improves patient compliance

Efficacy and tolerance in an Asian population

Results after 45 days of treatment with Biretix:

  • Significant reduction in sebum production (-57%)
  • Significant reduction in number of lesions (-50%)
  • 100% of patients reported good tolerance at end of study